InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2023-03-23 00:00:00 ET · period of report 2023-03-21 · accession 0001209191-23-020848 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-23 2023-03-21+ TYRA Harris Todd CEO, Dir M - OptEx $2.25 +19.2K 1.70M +1% +$43.3K
DM 2023-03-23 2023-03-21+ TYRA Harris Todd CEO, Dir S - Sale+OE $16.00 -19.2K 1.70M -1% -$307.8K
DM 2023-03-23 2023-03-21+ TYRA Harris Todd CEO, Dir M - OptEx $0.00 -19.2K 416.6K -4% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-21 M A 12,393 $2.25 1,713,669 D — —
2 Common Common Stock 2023-03-21 S D 12,393 $16.00 1,701,276 D — —
3 Common Common Stock 2023-03-22 M A 4,043 $2.25 1,705,319 D — —
4 Common Common Stock 2023-03-23 M A 2,800 $2.25 1,704,076 D — —
5 Common Common Stock 2023-03-23 S D 2,800 $16.00 1,701,276 D — —
6 Common Common Stock 2023-03-22 S D 4,043 $16.00 1,701,276 D — —
7 Derivative Stock Option (Right to Buy) 2023-03-23 M D 2,800 $0.00 409,776 D $2.25 · — to 2031-03-09 2,800 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
8 Derivative Stock Option (Right to Buy) 2023-03-22 M D 4,043 $0.00 412,576 D $2.25 · — to 2031-03-09 4,043 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
9 Derivative Stock Option (Right to Buy) 2023-03-21 M D 12,393 $0.00 416,619 D $2.25 · — to 2031-03-09 12,393 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.